Surveillance of urothelial carcinoma: Stage and grade migration, 1993-2005 and survival trends, 1993-2000

Cancer

Volumn 115, Issue 7, 2009, Pages 1435-1447

  David, Kevin A ^a,b   Mallin, Katherine ^c   Milowsky, Matthew I ^d   Ritchey, Jamie ^c   Carroll, Peter R ^e   Nanus, David M ^a,b,c,f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c AMERICAN COLLEGE OF SURGEONS   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NONE   (United States)

Author keywords

Grade; Stage migration; Survival; Urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; FEMALE; HUMAN; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; UNITED STATES; URETER CARCINOMA; UROGENITAL TRACT CANCER;

EID: 63449100234     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24147     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology. 1997;50:321-329.
3. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523-1525.
4. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167-3172.
5. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416-419.
6. Ung JO, Richie JP, Chen M, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002;60:458-463.
7. Freedland SJ, Presti JC, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741.
8. Chow W, Devesa SS, Warren JL, Fraumeni JF. Rising Incidence of Renal Cell Cancer in the United States. JAMA. 1999;281:1628-1631.
9. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203-205.
10. Homma Y, Kawabe K, Kitamura T, et al. Increased incidental detection and reduced mortality in renal cancer- recent retrospective analysis at 8 institutions. Int J Urol. 1995;2:77-80.
11. Gudbjartsson T, Thoroddsen A, Petursdottir V, Hardarson S, Magnusson J, Einarsson GV. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology. 2005;66:1186-1191.
12. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008;113:78-83.
13. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683-690.
14. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000: 71-72.
15. Commission on Cancer: Facility Oncology Registry Data Standards Revised for 2007. Chicago, IL: American College of Surgeons; 2007.
16. Shambaugh E, Young JL, Zippin CL, Um D, Akers C, Weiss MA. Statistics and Epidemiology for Cancer Registrars, Self-instruction Manual for Cancer Registrars, Book 7. Surveillance Epidemiology and End Results Program. Bethesda, MD: National Institutes of Health; 1995.
17. Kielar AZ, Ellis JH, Cohan RH, et al. Computed tomography urography: trends in positivity rates over time. J Com- put Assist Tomogr. 2008;32:46-53.
18. Dillman JR, Caoili EM, Cohan RH, Ellis JH, Francis IR, Schipper MJ. Detection of upper tract urothelial neoplasms: sensitivity of axial, coronal reformatted, and curved-planar reformatted image-types utilizing 16-row multi-detector CT urography. Abdom Imaging 2008;33:707-716.
19. Vaidya A, Soloway MS, Hawke C, Tiquert R, Civantos F. De novo muscle invasive bladder cancer: is there a change in trend? J Urol. 2001;165:47-50.
20. Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol. 1982;128:31-33.
21. Hopkins SC, Ford KS, Soloway MS. Invasive bladder cancer: support for screening. J Urol. 1983;130:61-64.
22. Nieder AM, Mackinnon JA, Huang Y, Fleming LE, Koniaris LG, Lee DJ. Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. J Urol 2008;179:491-495; discussion 495.
23. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45:387-396; discussion 96-97.
24. Carmack AJ, Soloway MS. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology. 2006;67(3 suppl 1):3-8; discussion 8-10.
25. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol. 2006;49:466-475; discussion 475-477.
26. Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem el HI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int. 2003;92:393-399.
27. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448.
28. Mills SE. Sternberg's Diagnostic Surgical Pathology. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2004.
29. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erick- stad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594-601.
30. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14-20.
31. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothe- lium. J Urol. 1985;133:403-407.
32. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with meth- otrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-1073.
33. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
34. Von der Maase H, Hansen SW, Roberts JT, et al. Gemci- tabine and cisplatin versus methotrexate, vinblastine, doxor- ubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multinational, multi-center, phase III study. J Clin Oncol. 2000;18:3068-3077.
35. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. JUrol. 2007;178:451-454.
36. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33-36.